Genmab A/S

NASDAQ:GMAB

Biotechnology

Healthcare
$50.97 -0.47%

-$0.12 today

Market cap
$31.43B
Beta
0.68
P/E (TTM)
18.7
EPS (TTM)
$13.36
52W Low $20.23High $35.43

Volume 2.96M

Average 1.85M

GMAB EBITDA Margin

EBITDA as a percentage of revenue.

Genmab A/SNASDAQ: GMAB

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to 37.3%

EBITDA Margin was 37.3% in Q2 FY2026, down 11.1 pp from a year earlier. On a trailing-twelve-month basis it was 29.5%. Over 3 fiscal years it narrowed by 14.7 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 15 analysts of 43.5% for the fiscal year ending Dec 2026, up from 35.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
37.3%+16.6 pp QoQ
Last fiscal yearDec 2025
35.9%-9.1 pp YoY
LTMJun 2026
29.5%— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-11.1 pp-5.7 pp+5.4 pp
1 year-9.1 pp+7.6 pp+16.7 pp
3 years-14.7 pp+7.6 pp+22.3 pp
5 years+7.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
35.9%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How GMAB compares with its peers on the latest reported figures

  • GMAB's LTM Jun 2026 EBITDA Margin of 29.5% is the 4th highest of the 10 companies compared; the peer median is -32.2%.
  • Over three fiscal years its change of -14.7 pp compares with a peer median of +28.0 pp.
GMAB Competitors Peer median
EBITDA Margin for GMAB and competitors
Company Period LTM level YoY 3-year change
CGENCompugen Ltd.LTM Mar 202648.0% +82.8 pp+491.0 pp
EXELExelixis, Inc.LTM Jul 202643.0% +6.3 pp+23.9 pp
INCYIncyte CorporationLTM Jun 202635.5% +6.0 pp+16.6 pp
GMABGenmab A/SLTM Jun 202629.5% —-14.7 pp
LEGNLegend Biotech CorporationLTM Sep 20267.3% +27.5 pp+333.4 pp
MGNXMacroGenics, Inc.LTM Mar 2026-32.2% -1.2 pp+32.0 pp
BNTXBioNTech SELTM Jun 2026-35.6% -34.2 pp-98.4 pp
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-48.8% +93.1 pp—
ADCTADC Therapeutics S.A.LTM Mar 2026-105.1% +22.1 pp-58.4 pp
RCUSArcus Biosciences, Inc.LTM Jun 2026-358.1% -250.5 pp+94.7 pp
ALXOALX Oncology Holdings Inc.FY2025— ——
Peer median (excluding GMAB) -32.2%+6.3 pp+28.0 pp

Competitors are the stored peer set for GMAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · DKK
FY2022
Dec 2022 · DKK
FY2023
Dec 2023 · DKK
FY2024
Dec 2024 · DKK
FY2025
Dec 2025 · USD
Revenue8.42B14.51B16.47B21.53B3.72B
Cost of Revenue00226M985M309.24M
Gross Profit8.42B14.51B16.25B20.54B3.41B
Gross Margin100.0%100.0%98.6%95.4%91.7%
Research & Development4.18B5.56B7.63B9.75B1.56B
Selling, General & Admin1.28B2.68B3.3B3.79B602.47M
Operating Expenses5.46B8.24B10.93B13.84B2.16B
Depreciation & Amortization248.99M362M293.62M413M71.06M
EBITDA4.18B7.35B6B9.7B1.34B
EBITDA Margin49.7%50.6%36.4%45.0%35.9%
Operating Income2.95B6.27B5.32B6.7B1.25B
Operating Margin35.1%43.2%32.3%31.1%33.6%
Interest Income197M324M939M995M138.11M
Interest Expense13M21M27M120M61.05M
Other Income / Expenses965M678M316M2.46B(46.04M)
Income Before Tax3.92B6.95B5.64B9.16B1.2B
Pre-Tax Margin46.5%47.9%34.2%42.6%32.4%
Income Tax Expense961M1.49B1.29B1.32B241.19M
Net Income2.96B5.45B4.35B7.84B963.76M
Net Margin35.1%37.6%26.4%36.4%25.9%
EPS (Basic)4.528.346.6012.141.55
EPS (Diluted)4.488.266.6012.141.54
Weighted Avg Shares653.96M653.87M659.15M646.33M621.51M
Weighted Avg Shares (Diluted)660.46M660.1M659.15M646.33M626.92M

Genmab A/S

NASDAQ:GMAB

Intrinsic Alpha fair value

Locked

Current Price

$50.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.